Cell Tissue Technology Sdn Bhd announces today that the Company's key product, MyDerm™ is listed among the 50 Innovation Business Opportunities (IBO) at the 6th Governance Council Meeting of Agensi Inovasi Malaysia (AIM).
According to AIM, MyDerm™ has the potential to generate a revenue of RM3.07 million in 3 years' time.
IBO is a continuous project under AIM that showcases locally developed potential innovations that are available for bidding by individuals and companies locally and abroad. The emphasis is to secure a business partner to commercialize the intellectual properties of universities and research institutes in Malaysia.
AIM's role is to bridge and facilitate the processes involved by publishing on their website every quarter the 50 projects available for interested parties to "bid”. Bidding here does not refer to any monetary transactions but indicates an interest. When a party bids for a project, it is required to provide information to AIM for screening with the owners of the IPs.
An introductory meeting will be held between the bidder and the IP owner to discuss potential modes of cooperation or collaboration.
MyDerm™ was included with 49 other projects which were announced by the Prime Minister, Dato' Seri Najib Tun Razak.
Details for bidding are now available at www.innovation.my.
CELL TISSUE TECHNOLOGY SDN BHD
Malaysia's FIRST Tissue Engineering Firm
Level 12, Clinical Block, UKM Medical Center,
Jalan Yaacob Latif, Bandar Tun Razak,
56000 Cheras, Kuala Lumpur, Malaysia.
Tel: +603 9545 3737
Proudly powered by CTTSB
© 2010-2017 Cell Tissue Technology Sdn Bhd,
a Company of Universiti Kebangsaan Malaysia.
All rights reserved.